Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Vorapaxar (Primary) ; Aspirin; Clopidogrel
- Indications Diabetes mellitus; Myocardial infarction
- Focus Pharmacodynamics
- Acronyms OPTIMUS-5
- 15 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2018.
- 15 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
- 08 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.